Compare ROMA & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROMA | TTRX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.4M | 121.3M |
| IPO Year | 2024 | N/A |
| Metric | ROMA | TTRX |
|---|---|---|
| Price | $2.24 | $3.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 954.1K | 42.3K |
| Earning Date | 03-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,640,101.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.60 | N/A |
| 52 Week Low | $0.58 | $2.57 |
| 52 Week High | $8.88 | $26.50 |
| Indicator | ROMA | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 39.04 |
| Support Level | $1.82 | $3.96 |
| Resistance Level | $8.88 | $5.02 |
| Average True Range (ATR) | 1.32 | 0.35 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 13.14 | 13.60 |
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.